Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma. Drugs used in

doxorubicin
avid
growth factor
pembrolizumab
cytopenia
  • 0 views
  • 15 Dec, 2021
  • 1 location
Study With Trabectedin Versus Adriamycin Plus Dacarbazine in Patients With Advanced Solitary Fibrous Tumor

Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor

  • 31 views
  • 08 Nov, 2021
  • 6 locations
MEK and Autophagy Inhibition in Metastatic/Locally Advanced Unresectable Neuroblastoma RAS (NRAS) Melanoma

approved in NRAS mutated melanoma as a second line treatment, because although the use of a MEK inhibitor (binimetinib) alone was superior to the gold standard chemotherapy (dacarbazine) in a phase 3 trial

  • 0 views
  • 25 Jan, 2021
  • 5 locations
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide, methyl prednisolone, citarabine and cisplatin). The schedules are delivered with low cumulative drug

  • 15 views
  • 23 Jan, 2021
  • 1 location
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

This is a prospective phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.

vincristine
epirubicin
camrelizumab
dacarbazine
lymphoma
  • 0 views
  • 27 Jan, 2021
  • 1 location
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

  • 0 views
  • 27 Jan, 2021
  • 1 location
Phase III Trial of Anlotinib Catequentinib in Advanced Alveolar Soft Part Sarcoma Leiomyosarcoma Synovial Sarcoma (APROMISS)

sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one

alveolar soft part sarcoma
anthracyclines
kidney function tests
renal function
measurable disease
  • 334 views
  • 01 Dec, 2021
  • 24 locations
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony

doxorubicin
colony stimulating factor
classical hodgkin lymphoma
cancer
graft versus host disease
  • 44 views
  • 21 Jan, 2022
  • 64 locations
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from

combination chemotherapy
topical steroids
alopecia
monoclonal antibodies
human immunodeficiency virus
  • 87 views
  • 19 Jan, 2022
  • 514 locations
Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to …

liposarcoma
systemic therapy
tubal occlusion
cancer chemotherapy
dedifferentiated liposarcoma
  • 0 views
  • 30 Jul, 2021
  • 23 locations